Screening and treatment of latent tuberculosis among patients receiving biologic agents, a national and international survey of rheumatologists

Nhu Quynh Tran, Melinda Garcia-Rosell, Debendra Pattanaik, Syed Raza, Laura Carbone

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: We sought to understand the current practice patterns of both US and international members of the American College of Rheumatology (ACR) in this regard. Methods: A set of questionnaires developed by a focus group of faculties and fellows of the Rheumatology Division of University of Tennessee Health Science Center, Memphis, TN,was sent electronically using an online survey tool to 4433 rheumatologists who are ACR members in the United States and internationally. Results: Seven hundred sixty-eight physicians out of 4433 ACR members responded to the electronic survey, with a response rate of 17.32%. The preferred screening method by most of the respondents was either tuberculin skin test (19%) or interferon Φ release assay (32%) or both. For treatment of latent tuberculosis infection (LTBI) overall, 49% of the respondents would refer management to infectious disease specialist or the health department, 37% would initiate isoniazid for 9 or 12 months, and 14% would use isoniazid for 6 months. Approximately 60% of respondents would initiate anti-tumor necrosis factor therapy after being on LTBI treatment for 1 month. The other respondents were almost equally divided among the 3 responses: 2, 3, 6, or 9 months. Conclusions: There is a large disagreement regarding the method used and howoften to screen for LTBI after initiating biologic therapy and how soon biologic treatment would be started after initiating LTBI therapy. Another disagreement exists regarding the duration of LTBI therapy. The information obtained from the survey can be taken into account when ACR or other international member organizations formulate future recommendations regarding screening and treatment of LTBI.

Original languageEnglish (US)
Pages (from-to)6-11
Number of pages6
JournalJournal of Clinical Rheumatology
Volume23
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Latent Tuberculosis
Biological Factors
Rheumatology
Isoniazid
Therapeutics
Tuberculin Test
Biological Therapy
Surveys and Questionnaires
Rheumatologists
Health
Skin Tests
Focus Groups
Interferons
Communicable Diseases
Tumor Necrosis Factor-alpha
Physicians

All Science Journal Classification (ASJC) codes

  • Rheumatology

Cite this

Screening and treatment of latent tuberculosis among patients receiving biologic agents, a national and international survey of rheumatologists. / Tran, Nhu Quynh; Garcia-Rosell, Melinda; Pattanaik, Debendra; Raza, Syed; Carbone, Laura.

In: Journal of Clinical Rheumatology, Vol. 23, No. 1, 01.01.2017, p. 6-11.

Research output: Contribution to journalArticle

@article{0ba4bc9b78b7457788555bae6ad02d42,
title = "Screening and treatment of latent tuberculosis among patients receiving biologic agents, a national and international survey of rheumatologists",
abstract = "Objective: We sought to understand the current practice patterns of both US and international members of the American College of Rheumatology (ACR) in this regard. Methods: A set of questionnaires developed by a focus group of faculties and fellows of the Rheumatology Division of University of Tennessee Health Science Center, Memphis, TN,was sent electronically using an online survey tool to 4433 rheumatologists who are ACR members in the United States and internationally. Results: Seven hundred sixty-eight physicians out of 4433 ACR members responded to the electronic survey, with a response rate of 17.32{\%}. The preferred screening method by most of the respondents was either tuberculin skin test (19{\%}) or interferon Φ release assay (32{\%}) or both. For treatment of latent tuberculosis infection (LTBI) overall, 49{\%} of the respondents would refer management to infectious disease specialist or the health department, 37{\%} would initiate isoniazid for 9 or 12 months, and 14{\%} would use isoniazid for 6 months. Approximately 60{\%} of respondents would initiate anti-tumor necrosis factor therapy after being on LTBI treatment for 1 month. The other respondents were almost equally divided among the 3 responses: 2, 3, 6, or 9 months. Conclusions: There is a large disagreement regarding the method used and howoften to screen for LTBI after initiating biologic therapy and how soon biologic treatment would be started after initiating LTBI therapy. Another disagreement exists regarding the duration of LTBI therapy. The information obtained from the survey can be taken into account when ACR or other international member organizations formulate future recommendations regarding screening and treatment of LTBI.",
author = "Tran, {Nhu Quynh} and Melinda Garcia-Rosell and Debendra Pattanaik and Syed Raza and Laura Carbone",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/RHU.0000000000000466",
language = "English (US)",
volume = "23",
pages = "6--11",
journal = "Journal of Clinical Rheumatology",
issn = "1076-1608",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Screening and treatment of latent tuberculosis among patients receiving biologic agents, a national and international survey of rheumatologists

AU - Tran, Nhu Quynh

AU - Garcia-Rosell, Melinda

AU - Pattanaik, Debendra

AU - Raza, Syed

AU - Carbone, Laura

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: We sought to understand the current practice patterns of both US and international members of the American College of Rheumatology (ACR) in this regard. Methods: A set of questionnaires developed by a focus group of faculties and fellows of the Rheumatology Division of University of Tennessee Health Science Center, Memphis, TN,was sent electronically using an online survey tool to 4433 rheumatologists who are ACR members in the United States and internationally. Results: Seven hundred sixty-eight physicians out of 4433 ACR members responded to the electronic survey, with a response rate of 17.32%. The preferred screening method by most of the respondents was either tuberculin skin test (19%) or interferon Φ release assay (32%) or both. For treatment of latent tuberculosis infection (LTBI) overall, 49% of the respondents would refer management to infectious disease specialist or the health department, 37% would initiate isoniazid for 9 or 12 months, and 14% would use isoniazid for 6 months. Approximately 60% of respondents would initiate anti-tumor necrosis factor therapy after being on LTBI treatment for 1 month. The other respondents were almost equally divided among the 3 responses: 2, 3, 6, or 9 months. Conclusions: There is a large disagreement regarding the method used and howoften to screen for LTBI after initiating biologic therapy and how soon biologic treatment would be started after initiating LTBI therapy. Another disagreement exists regarding the duration of LTBI therapy. The information obtained from the survey can be taken into account when ACR or other international member organizations formulate future recommendations regarding screening and treatment of LTBI.

AB - Objective: We sought to understand the current practice patterns of both US and international members of the American College of Rheumatology (ACR) in this regard. Methods: A set of questionnaires developed by a focus group of faculties and fellows of the Rheumatology Division of University of Tennessee Health Science Center, Memphis, TN,was sent electronically using an online survey tool to 4433 rheumatologists who are ACR members in the United States and internationally. Results: Seven hundred sixty-eight physicians out of 4433 ACR members responded to the electronic survey, with a response rate of 17.32%. The preferred screening method by most of the respondents was either tuberculin skin test (19%) or interferon Φ release assay (32%) or both. For treatment of latent tuberculosis infection (LTBI) overall, 49% of the respondents would refer management to infectious disease specialist or the health department, 37% would initiate isoniazid for 9 or 12 months, and 14% would use isoniazid for 6 months. Approximately 60% of respondents would initiate anti-tumor necrosis factor therapy after being on LTBI treatment for 1 month. The other respondents were almost equally divided among the 3 responses: 2, 3, 6, or 9 months. Conclusions: There is a large disagreement regarding the method used and howoften to screen for LTBI after initiating biologic therapy and how soon biologic treatment would be started after initiating LTBI therapy. Another disagreement exists regarding the duration of LTBI therapy. The information obtained from the survey can be taken into account when ACR or other international member organizations formulate future recommendations regarding screening and treatment of LTBI.

UR - http://www.scopus.com/inward/record.url?scp=85007365547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007365547&partnerID=8YFLogxK

U2 - 10.1097/RHU.0000000000000466

DO - 10.1097/RHU.0000000000000466

M3 - Article

VL - 23

SP - 6

EP - 11

JO - Journal of Clinical Rheumatology

JF - Journal of Clinical Rheumatology

SN - 1076-1608

IS - 1

ER -